Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction.
暂无分享,去创建一个
[1] Jingwei Wu,et al. Association Between Adherence Measurements of Metoprolol and Health Care Utilization in Older Patients with Heart Failure , 2005, Clinical pharmacology and therapeutics.
[2] M. Prins,et al. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. , 2004 .
[3] M. Packer. Do β-blockers prolong survival in heart failure only by inhibiting the β1-receptor? A perspective on the results of the COMET trial , 2003 .
[4] Anke Richter,et al. The impact of reducing dose frequency on health outcomes. , 2003, Clinical therapeutics.
[5] Antonio Addis,et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. , 2002, Clinical therapeutics.
[6] J. Cramer,et al. A systematic review of the associations between dose regimens and medication compliance. , 2001, Clinical therapeutics.
[7] D. DeMets,et al. Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.
[8] H. Dargie,et al. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial , 2001, The Lancet.
[9] S. Gottlieb,et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. , 1996, Circulation.
[10] J. A. Bowers,et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. , 1996, Circulation.
[11] J. Cohn,et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.